P27 Analogue CP2

P27 Analogue CP2 is a macrocyclic peptide inhibitor targeting the SCFSkp2/Cks1 E3 ubiquitin ligase (Kd=32 nM) . p27 Analogue CP2 blocks SCFSkp2/Cks1-mediated ubiquitylation and degradation of p27, restoring p27 levels and inhibiting cell proliferation. p27 Analogue CP2 is promising for research of cancers dependent on Skp2 overexpression such as breast cancer[1].

Product Specifications

UNSPSC

12352209

Target

E1/E2/E3 Enzyme

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=C(NCC(N[C@@H](CO)C(N[C@@H](CCN1C=C(CCNC(NCCC2=CN(CCC[C@@H](C(N[C@H](C(O)=O)CCCCN)=O)NC([C@H]3N(C([C@H]([C@H](OP(O)(O)=O)C)NC([C@@H]4CCC(N)=O)=O)=O)CCC3)=O)N=N2)=O)N=N1)C(N[C@@H](CCC(O)=O)C(N4)=O)=O)=O)=O)[C@@H](N)C

Molecular Formula

C51H83N20O20P

Molecular Weight

1327.30

References & Citations

[1]Zenkevičiūtė G, et al. Development of constrained peptide inhibitors targeting an oncogenic E3 ubiquitin ligase[J]. bioRxiv, 2023: 2023.04. 27.535981.